About the company

Macrocyclics, Inc., a manufacturer of customized chelating agents, is dedicated to leading-edge development of new chelation chemistry platforms critical for advancement of diagnostic and therapeutic medicine.

Macrocyclics’ partners

Research

Providing tools and solutions in the field of nuclear medicine for site-specific bioconjugation, advanced chelating agent technology, and peptide intermediates. 

GMP Manufacturing

Macrocyclics introduced its cGMP manufacturing services in 2005. Our quality system is designed specifically for the manufacture of APIs to be used in clinical trials.

Services

Our team provides comprehensive technical support for all catalog products.  We also offer custom synthesis, contract manufacturing, and project consultation tailored to specific needs.

What’s In Store?

At Macrocyclics, we listen to client requests and are excited to introduce new products in response to your ideas and suggestions.

c-220Featured product

DOTATATE

Macrocyclics is proud to introduce DOTATATE, its first peptide conjugate. Read more here

Featured product

DOTAGA-tetra (t-Bu ester)

Macrocyclics is proud to introduce DOTAGA-tetra (t-Bu ester).
Read more here

 

News & Events

Stay informed on new technology, partnerships, collaborations, and events.

events

May 03, 2017

EANM – European Association of Nuclear Medicine – 2017

Please visit the Macrocyclics team at Booth #234 in Hall X2 between October 20 & 25…

Read More

events

May 03, 2017

SNMMI – Society of Nuclear Medicine and Molecular Imaging 2017

Please visit the Macrocyclics team at Booth #857 between June 10 & 14…

Read More

events

May 03, 2017

10th International Symposium on Targeted Alpha Therapy, TAT-10

Meet us at the 10th International Symposium on Targeted Alpha Therapy.

Read More

news

Nov 01, 2016

Macrocyclics produces cGMP peptide in support of NET clinical trial

Macrocyclics was contracted by Radiomedix and AREVA Med to produce the cGMP peptide conjugate that will b…

Read More